{"disease":{"id":"kras-g12c","name":"kras g12c"},"drugs":{"marketed":[{"drug_id":"sotorasib","indication_name":"KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Lumakras","generic_name":"SOTORASIB","company_name":"Amgen","drug_phase":"marketed","molecular_target":"GTPase KRas","drug_class":"","quality_score":65,"revenue":"300","mechanism":"Lumakras works by covalently binding to the KRAS G12C mutation, thereby blocking the protein's ability to promote cancer cell growth."},{"drug_id":"adagrasib","indication_name":"KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Krazati","generic_name":"ADAGRASIB","company_name":"Bristol-Myers Squibb","drug_phase":"marketed","molecular_target":"GTPase KRas","drug_class":"","quality_score":66,"revenue":"205","mechanism":"Krazati works by binding to and inhibiting the GTPase activity of the KRAS G12C protein, preventing it from sending signals that promote cancer cell growth."}],"pipeline":[],"offLabel":[],"totalMarketed":2,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT03600883","title":"A Phase 1/2, Study Evaluating the Safety, Tolerability, PK, and Efficacy of Sotorasib (AMG 510) in Subjects With Solid Tumors With a Specific KRAS Mutation (CodeBreaK 100)","phase":"PHASE1, PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":713,"lead_sponsor_name":"Amgen","has_results":false},{"nct_id":"NCT04185883","title":"Sotorasib Activity in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreak 101)","phase":"PHASE1","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":610,"lead_sponsor_name":"Amgen","has_results":false},{"nct_id":"NCT06793215","title":"A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":600,"lead_sponsor_name":"Hoffmann-La Roche","has_results":false},{"nct_id":"NCT05273047","title":"RW Efficacy of Sotorasib in KRAS G12C-mutated Metastatic NSCLC","phase":"","overall_status":"UNKNOWN","enrollment_count":458,"lead_sponsor_name":"Intergroupe Francophone de Cancerologie Thoracique","has_results":false},{"nct_id":"NCT04303780","title":"Study to Compare AMG 510 \"Proposed INN Sotorasib\" With Docetaxel in Non Small Cell Lung Cancer (NSCLC) (CodeBreak 200).","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":345,"lead_sponsor_name":"Amgen","has_results":true},{"nct_id":"NCT04699188","title":"Study of JDQ443 in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation","phase":"PHASE1, PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":344,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":false},{"nct_id":"NCT06497556","title":"A Study Evaluating the Efficacy and Safety of Divarasib Versus Sotorasib or Adagrasib in Participants With Previously Treated KRAS G12C-positive Advanced or Metastatic Non-Small Cell Lung Cancer","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":338,"lead_sponsor_name":"Hoffmann-La Roche","has_results":false},{"nct_id":"NCT05005234","title":"A Study of GFH925 in Patients With Advanced Solid Tumors With KRAS G12C Mutations","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":334,"lead_sponsor_name":"Innovent Biologics (Suzhou) Co. Ltd.","has_results":false},{"nct_id":"NCT07124884","title":"5-fluorouracil Plus Panitumumab (Anti-EGFR) and Sotorasib (KRAS G12C Inhibitor) in First-line Treatment of Patients Non-eligible for a Doublet/Triplet Chemotherapy With Advanced Unresectab","phase":"PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":300,"lead_sponsor_name":"Federation Francophone de Cancerologie Digestive","has_results":false},{"nct_id":"NCT06720987","title":"A Study to Investigate the Safety and Efficacy of KQB365 as Monotherapy and in Combination in Participants With Advanced Solid Malignancies","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":128,"lead_sponsor_name":"Kumquat Biosciences Inc.","has_results":false},{"nct_id":"NCT06435455","title":"GH21 Combined With D-1553 in KRAS G12C Mutant Advanced Solid Tumors","phase":"PHASE1, PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":126,"lead_sponsor_name":"Suzhou Genhouse Bio Co., Ltd.","has_results":false},{"nct_id":"NCT06659341","title":"A Phase I Study of BAY3498264 Given Together With Sotorasib in Participants Who Have Advanced Solid Cancers With Specific Genetic Changes Called KRASG12C Mutation","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":104,"lead_sponsor_name":"Bayer","has_results":false},{"nct_id":"NCT05445843","title":"Study of Efficacy and Safety of JDQ443 Single-agent as First-line Treatment for Patients With Locally Advanced or Metastatic KRAS G12C- Mutated Non-small Cell Lung Cancer With a PD-L1 Expression < 1% or a PD-L1 Expression ≥ 1% and an STK11 Co-mutation.","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":95,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":true},{"nct_id":"NCT06008288","title":"A Phase II Study Evaluating JAB-21822 Monotherapy in Adult Patients With Pancreatic Cancer and Other Solid Tumors Harboring the KRAS p.G12C Mutation.","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":88,"lead_sponsor_name":"Allist Pharmaceuticals, Inc.","has_results":false},{"nct_id":"NCT05358249","title":"Platform Study of JDQ443 in Combinations in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation","phase":"PHASE1, PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":74,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":false},{"nct_id":"NCT07339839","title":"Glecirasib Combined With Ivonescimab for First-line Treatment of KRAS G12C-mutated NSCLC","phase":"PHASE1, PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":42,"lead_sponsor_name":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","has_results":false},{"nct_id":"NCT05631249","title":"Sotorasib in Previously Treated Locally Advanced or Metastatic NSCLC Subjects With Mutated KRAS p.G12C","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":40,"lead_sponsor_name":"Gustave Roussy, Cancer Campus, Grand Paris","has_results":false},{"nct_id":"NCT07122882","title":"Integrated Genomics in Oncogene-driven NSCLC With Acquired Resistance","phase":"","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":40,"lead_sponsor_name":"Chang Gung Memorial Hospital","has_results":false},{"nct_id":"NCT07468071","title":"Rollover Study for Participants Who Have Been Treated With and Are Continuing to Benefit From Opnurasib as a Single Agent or in Combination With Other Study Treatments","phase":"PHASE1, PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":40,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":false},{"nct_id":"NCT06936644","title":"A Multicenter, Single-arm Phase II Study to Evaluate the Efficacy and Safety of Fulzerasib (IBI351) in Combination With Ivonescimab (AK-112) in First-line Treatment of Advanced or Metastatic Non-small Cell Lung Cancer Patients With KRAS G12C Mutation","phase":"PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":39,"lead_sponsor_name":"Shanghai Chest Hospital","has_results":false},{"nct_id":"NCT07472478","title":"Phase II Neoadjuvant Study of Garsorasib Followed by Ivonescimab Plus Chemotherapy in Resectable Stage IIA-IIIB KRAS G12C-Mutant NSCLC (GIVEN Study)","phase":"PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":32,"lead_sponsor_name":"Guangdong Provincial People's Hospital","has_results":false},{"nct_id":"NCT06412198","title":"A Multicenter Phase 1b/2 Study of Adagrasib, Cetuximab, and Cemiplimab for Metastatic Colorectal Cancer Harboring KRAS G12C Mutations","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":31,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT07492342","title":"Fulzerasib Sequential Sintilimab Plus Platinum-Doublet Neoadjuvant Therapy for Resectable KRAS G12C-Mutant NSCLC","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":30,"lead_sponsor_name":"Jianxing He","has_results":false},{"nct_id":"NCT06248606","title":"Adagrasib + SRS for Patients With Metastatic KRAS G12C-mutated NSCLC With Untreated Brain Metastases","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":30,"lead_sponsor_name":"Ryan Gentzler, MD","has_results":false},{"nct_id":"NCT05398094","title":"Clinical Trial of AMG510 in Stage III Unresectable NSCLC KRAS p.G12C Patients and Ineligible for Chemo-radiotherapy","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":19,"lead_sponsor_name":"Fundación GECP","has_results":false},{"nct_id":"NCT04380753","title":"AMG 510 Ethnic Sensitivity Study (CodeBreaK 105).","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":12,"lead_sponsor_name":"Amgen","has_results":true},{"nct_id":"NCT05631899","title":"CAR-DC Vaccine and ICIs in Local Advanced/Metastatic Solid Tumors","phase":"PHASE1","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":9,"lead_sponsor_name":"Chinese PLA General Hospital","has_results":false},{"nct_id":"NCT05251038","title":"Study of Sotorasib Combined With Chemotherapy for Second Line Treatment of Pancreas Cancer","phase":"PHASE1, PHASE2","overall_status":"WITHDRAWN","enrollment_count":0,"lead_sponsor_name":"Devalingam Mahalingam","has_results":false},{"nct_id":"NCT07083479","title":"Expanded Access Protocol of ELI-002-102 in Subjects With KRAS/NRAS Mutated Pancreatic Ductal Adenocarcinoma","phase":"","overall_status":"AVAILABLE","enrollment_count":null,"lead_sponsor_name":"Elicio Therapeutics","has_results":false}],"total":29},"guidelines":[],"source":"Drug Landscape verified database"}